These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25817540)

  • 1. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
    He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
    Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
    Wang Y; Li Q; Xing S; Zhang H; Li D
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
    Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
    Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
    Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
    Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
    Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma.
    Rabani H; Ziv M; Lavi N; Aviv A; Suriu C; Shalata A; Haddid Y; Tadmor T
    Leuk Res; 2020 Dec; 99():106476. PubMed ID: 33171301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chromosome 13q deletion detected by interphase FISH in multiple myeloma: a study of 100 cases in China].
    Li Q; Lu Y; Wang YF; Liu XP; Qi JY; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1979-82. PubMed ID: 19950573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma.
    Bang SM; Kim YR; Cho HI; Chi HS; Seo EJ; Park CJ; Yoo SJ; Kim HC; Chun HG; Min HC; Oh BR; Kim TY; Lee JH; Lee DS
    Cancer Genet Cytogenet; 2006 Jul; 168(2):124-32. PubMed ID: 16843102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.
    Govindasamy P; Pandurangan P; Tarigopula A; Mani R; R Samuel C
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):235-241. PubMed ID: 30678438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
    Chang H; Sloan S; Li D; Keith Stewart A
    Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
    Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
    Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
    Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of deletion of the long arm of chromosome 13 and translocation of immunoglobulin heavy chain gene by interphase fluorescence in situ hybridization in patients with multiple myeloma].
    Sun WL; Wu YJ; Li H; Wang X; Zhuang JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):485-90. PubMed ID: 18795626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
    Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
    Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
    Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.